The Drugs Controller General of India DCGI approved the single-shot Sputnik Light vaccine for use in emergency situations in India, said Dr Reddy's Laboratories Ltd. on Monday.
Sputnik Light is a one-dose vaccine and the same as the first component -- recombinant human adenoviruses serotype number 26 rAd 26 - of the two-dose Sputnik V vaccine. Following the Phase III clinical trial of the single-shot Sputnik Light vaccine in India, Dr. Reddy s submitted its application to the DCGI in December 2021, in addition to the data from the clinical trial in Russia, the company said in a statement.
The standalone Sputnik Light vaccine is the latest vaccine approved by the DCGI as part of India's national inoculation effort against COVID 19. Sputnik Light is the 9th COVID 19 vaccine approved by the drug regulators for use among the public. The one-shot vaccine is the second COVID 19 vaccine to be made available in India by Dr Reddy s.
DCGI has granted emergency use permission for Single-dose Sputnik Light COVID 19 vaccine in India. This is the 9th COVID 19 vaccine in the country. In a tweet, Union Health Minister Mansukh Mandaviya said that this will strengthen the nation's collective fight against the epidemic.
Sputnik Light has been approved in over 30 countries around the world, including Russia, UAE, Philippines and Argentina. An independent comparative study conducted by the Spallanzani Institute in Italy showed that Sputnik V shows strong protection against the Omicron variant, with over two times higher virus neutralizing activity compared to the Pfizer vaccine.
A preliminary study of the Gamaleya Center which developed the vaccine has found that Sputnik Light significantly increases the virus-neutralizing activity against Omicron, which is comparable to titers observed after Sputnik V against wild-type viruses, associated with high levels of protection.
A unique comparative study conducted at the Lazzaro Spallanzani National Institute for Infectious Diseases in Italy by a team of 12 Italian and 9 Russian scientists led by Francesco Vaia, Director of Spallanzani Institute and Alexander Gintsburg, Director of the Gamaleya Center, shows that Sputnik V vaccine demonstrates more than 2 times higher titers of virus neutralizing antibodies to Omicron B. The study was conducted in the same laboratory conditions on similar serum samples from individuals vaccinated with Sputnik V and Pfizer with similar levels of IgG antibodies and virus neutralizing activity against the Wuhan variant 2.1 times higher than 2 doses of Pfizer vaccine 2.1 times higher in total and 2.6 times higher in 3 months after vaccination. Sputnik V showed a significant reduction of virus neutralizing activity against Omicron compared to reference Wuhan variant than Pfizer vaccine 8.1 fold reduction for Sputnik V in comparison to 21.4 fold reduction for Pfizer vaccine According to the Russian Direct Investment Fund RDIF based on data collected by the Spallanzani Institute and results of previous studies, heterologous mix match boosting with Sputnik Light is a solution to increase the effectiveness of the vaccine and extend the booster protection period as optimal aden
In September 2020, Dr Reddy s partnered with the RDIF to conduct clinical trials of Sputnik V and distribute the vaccine in India. In April 2021, the DCGI granted approval for the two-dose Sputnik V vaccine for use in emergency situations in India.
India has eight more vaccines approved under its national COVID 19 immunisation program. There are Oxford-AstraZeneca developed Covishield manufactured by Pune based Serum Institute of India, Bharat Biotech s Covaxin, Russia s Sputnik V imported by Dr Reddy s, Zydus Cadila s ZyCoV-D, Johnson and Johnson by USA based Janssen Pharmaceutical Companies, mRNA vaccine from Moderna Moderna, Inc an American pharmaceutical and biotechnology. While India is still waiting for Johnson and Johnson and Moderna vaccines, Zydus Cadila said last week it started supplying doses to the government of India.
The government approved in December 2021 Covovax, a protein subunit COVID 19 vaccine developed by Novavax Inc., an American biotechnology company based in Gaithersburg, to be sold and manufactured in India by Serum Institute of India SII as Covovax. Corbevax is a protein subunit vaccine approved by India. It was developed by Texas Children's Hospital at the Baylor College of Medicine in Houston, Texas and Dynavax Technologies in Emeryville California. The development and production of BioE is licensed to Indian biopharmaceutical firm Biological E. Limited BioE.
India's COVID 19 vaccine coverage has exceeded 169.63 Cr 1,69, 63,80, 755 with the administration of more than 14.70 lakh Doses 14,70, 053 vaccine doses in the last 24 hours. India's COVID 19 total tally continues to swell slowly. In the last 24 hours, 83,876 new cases were reported. India's Active Caseload is currently at 11,08, 938. Active cases constitute 2.62 per cent of the country's total positive cases.